Agilent Technologies Opened New Boulder Laboratory
The facility will support the development of enzymatic ligation for oligonucleotide therapeutics.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you feel business expansions in your area signal a healthier local economy?
Agilent Technologies has expanded its footprint in Boulder, Colorado, with a new laboratory dedicated to oligonucleotide manufacturing. The space will focus on developing enzymatic ligation processes for therapeutic molecules.
Why it matters
This laboratory provides a dedicated environment for Agilent to evaluate enzymatic ligation as a complement to traditional manufacturing methods. It allows the company to better address specific customer needs for developing siRNA and antisense therapies.
The laboratory focuses on enzymatic ligation, which joins shorter oligonucleotide fragments into longer therapeutic molecules. This process is being evaluated to complement existing solid-phase phosphoramidite synthesis techniques.
The players
Agilent Technologies
This is a global analytical instrumentation and life sciences company that provides solutions for clinical and research laboratories.
The details
The Boulder facility is designed to support the development and scale-up of manufacturing technologies for siRNA and antisense oligonucleotides. By focusing on enzymatic ligation, Agilent aims to enhance its services for creating complex therapeutic molecules.
Timeline
October 5, 2026: Agilent announced the opening of the new laboratory space.
November 2026: The facility is scheduled to begin initial customer programs.
The Tech Race
The laboratory evaluates enzymatic ligation as a complement to solid-phase phosphoramidite synthesis. This move marks a strategic shift toward more efficient enzymatic methods to improve the production of complex oligonucleotide therapeutics.
The expansion of this facility signifies an increase in the regional capacity to develop specialized medicines. Future therapeutic availability for patients may improve as these advanced manufacturing technologies reach the commercial scale.
The takeaway
Advancements in enzymatic ligation could significantly streamline the production of specialized oligonucleotide drugs. This development highlights how biotech firms are increasingly looking to hybrid manufacturing models to accelerate the delivery of novel therapies.
What happens next
Initial customer programs are scheduled to commence at the new Boulder laboratory in November 2026.
Further reading
Learn more about the latest industry trends in the Biotech section.
Source note: This article includes information reported by Chemanager-online.
Live Poll
Do you feel business expansions in your area signal a healthier local economy?
